Related Experiment Video
Updated: Jul 16, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
A critical overview of the pharmacologic management of treatment-resistant depression
Andrew A Nierenberg1, Judith Katz, Maurizio Fava
1Depression Clinical and Research Program, Massachusetts General Hospital, 50 Staniford Street, Boston, MA 02114, USA. anierenberg@partners.org
Abstract:
Major depressive disorder is a frequent, serious disorder that usually responds partially to treatment and leaves many patients with treatment resistance. This article reviews and critically evaluates the evidence for the management of treatment-resistant depression and examines pharmacologic approaches to alleviate the suffering of patients who benefit insufficiently from initial treatment.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs